Knowing stock market today at a glance

Arcturus Therapeutics Soars 11.22% on Q1 Earnings, Strategic Shift

Mover TrackerTuesday, May 13, 2025 8:16 am ET

1min read

On May 13, 2025, Arcturus Therapeutics' stock surged by 11.22% in pre-market trading, reflecting a significant bullish sentiment among investors.

Analysts have given Arcturus Therapeutics a consensus rating of Buy, with a price prediction of $47.94 for 2025. This optimistic outlook is supported by the average target price, which implies a potential upside of 434.94% from the current price.

Arcturus Therapeutics reported its Q1 2025 financials, showing revenues of $29.4 million, a net loss of $14.1 million, and cash and equivalents of $273.8 million. The company also highlighted significant cost reductions in research and development (R&D) and general and administrative (G&A) expenses.

The company's strategic shift toward cystic fibrosis (CF) and over-the-counter (OTC) mRNA therapeutics has extended its cash runway into 2028, providing a stable financial outlook for the near future.

Disclaimer: The news articles available on this platform are generated in whole or in part by artificial intelligence and may not have been reviewed or fact checked by human editors. While we make reasonable efforts to ensure the quality and accuracy of the content, we make no representations or warranties, express or implied, as to the truthfulness, reliability, completeness, or timeliness of any information provided. It is your sole responsibility to independently verify any facts, statements, or claims prior to acting upon them. Ainvest Fintech Inc expressly disclaims all liability for any loss, damage, or harm arising from the use of or reliance on AI-generated content, including but not limited to direct, indirect, incidental, or consequential damages.